Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Cutaneous Pathology"
DOI: 10.1111/cup.12857
Abstract: To the Editor , BRAF inhibitors (BRAFi) vemurafenib and dabrafenib have become the standard of care of metastatic melanoma. Well-described cutaneous side effects include secondary tumors such as squamous cell carcinomas and secondary melanomas and…
read more here.
Keywords:
literature;
brafi;
panniculitis emerging;
brafi associated ... See more keywords